Infection risk in inflammatory bowel disease patients treated with vedolizumab: a systematic review and meta-analysis - Top-Institutions - MDSpire

Infection risk in inflammatory bowel disease patients treated with vedolizumab: a systematic review and meta-analysis

  • By

  • Lidan Zhang

  • Xiaogang Hao

  • Yidan Cui

  • Wenjian Yan

  • Kun Shang

  • Xin Zhang

  • June 11, 2026

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Gastroenterology

  • #2

    The Mount Sinai Hospital / Icahn School of Medicine at Mount Sinai
    The Mount Sinai Hospital / Icahn School of Medicine at Mount Sinai

    New York, New York

    Key Differentiators

    • Gastroenterology

Original Source(s)

Infection risk in inflammatory bowel disease patients treated with vedolizumab: a systematic review and meta-analysis

  • by Lidan Zhang, Xiaogang Hao, Yidan Cui, Wenjian Yan, Kun Shang, Xin Zhang

  • June 11, 2026

Related Content

Gut microbial bile salt hydrolase as a metabolic gatekeeper in digestive homeostasis and disease

Exploring Comorbidity Patterns in Inflammatory Bowel Disease: Insights from the All of Us Research Program

Bioinformatics-driven insights: rapamycin-mediated CaMK2D inhibition alleviates intestinal ischemia-reperfusion injury